Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis is a topic covered in the Evidence-Based Medicine Guidelines.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis ID - 451691 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451691/all/Iloprost_and_cisaprost_for_Raynaud's_phenomenon_in_progressive_systemic_sclerosis PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -